|
Non-metastatic prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, localizing a BCR with PSMA PET/CT remains challenging in patients with low prostate-specific antigen (PSA) values.
|
31481580 |
2020 |
|
Non-metastatic prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 93 patients with biochemically recurrent prostate cancer underwent [<sup>68</sup>Ga]PSMA-11 PET/CT and subsequently a whole-body integrated PET/MRI examination.
|
31482413 |
2019 |
|
Non-metastatic prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prostate specific membrane antigen targeted radiotracers are likely effective to detect biochemically recurrent prostate cancer at low prostate specific antigen levels.
|
30829130 |
2019 |
|
Non-metastatic prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this single-arm prospective trial conducted at University of California, San Francisco and University of California, Los Angeles, 635 patients with biochemically recurrent prostate cancer after prostatectomy (n = 262, 41%), radiation therapy (n = 169, 27%), or both (n = 204, 32%) underwent 68Ga-PSMA-11 PET.
|
30920593 |
2019 |
|
Non-metastatic prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ga-labeled prostate-specific membrane antigen inhibitors and Ga-labeled gastrin-releasing peptide receptor antagonists showed interesting results for staging biochemically recurrent prostate cancer.
|
31246685 |
2019 |
|
Non-metastatic prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prostate-specific membrane antigen (PSMA) PET/CT is increasingly used in patients with biochemically recurrent prostate cancer (BCR), mostly using gallium-68 (<sup>168</sup>Ga)-labelled radiotracers.
|
31230088 |
2019 |
|
Non-metastatic prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The use of <sup>68</sup>Ga-PET/CT PSMA to determine patterns of disease for biochemically recurrent prostate cancer following primary radiotherapy.
|
31363165 |
2019 |
|
Non-metastatic prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical impact of PSMA-based <sup>18</sup>F-DCFBC PET/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy.
|
28894899 |
2018 |
|
Non-metastatic prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Imaging of biochemically recurrent prostate cancer has been established as a widely accepted clinical indication for PSMA ligand PET/CT in many parts of the world because of the results of multiple, primarily retrospective, studies that indicate superior detection efficacy compared with standard-of-care imaging.
|
28687599 |
2017 |
|
Non-metastatic prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Optimal MRI sequences for <sup>68</sup>Ga-PSMA-11 PET/MRI in evaluation of biochemically recurrent prostate cancer.
|
28929350 |
2017 |
|
Non-metastatic prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Impact of <sup>68</sup>Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer.
|
28522741 |
2017 |
|
Non-metastatic prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since biochemically recurrent prostate cancer is defined by technological limitations of radiographic detection, as new imaging (i.e., PSMA) strategies are developed, it may alter how the disease is monitored and perhaps managed.
|
28434181 |
2017 |